Alumni News: Cristal Therapeutics signs co-exclusive licence agreement with Curapath to expand CliCr® platform

LS@W alumnus Cristal Therapeutics has reached an important milestone in the development and adoption of its CliCr® bioconjugation platform. The company has entered into a co-exclusive licence agreement with Curapath, a leading CDMO specialising in polymer and lipid-based drug delivery systems.

Under the agreement, Curapath will implement CliCr® copper-free click chemistry for site-specific, rapid and stable conjugation of biomolecules to polymeric and lipid nanoparticles (LNPs)—a key enabling step for next-generation targeted therapies, including extrahepatic nucleic acid delivery. Both companies will have the right to grant sublicences within this growing application area.

According to Cristal Therapeutics, the partnership marks a significant step in establishing CliCr® as a scalable and robust technology for advanced drug delivery. Curapath emphasises that integrating CliCr® strengthens its capabilities in developing precise and stable bioconjugation solutions for novel therapeutic modalities.

This collaboration highlights the continued progress of Cristal Therapeutics and its contribution to advancing innovative technologies within the Dutch life sciences ecosystem.

Source: LinkedIn